Pfizer Lied to Us Again

Viral load rebounds were also more common in the Paxlovid group, and symptom and viral load rebounds combined were more common among those taking Pfizer’s treatment. While percentages were generally low, other studies have pegged Paxlovid-associated rebound as occurring nearly one quarter of the time. 

Advertisement

So it’s not particularly effective at reducing symptoms or resolving them more quickly, doesn’t lead to statistically significant improvements in the most severe outcomes, and is more likely to result in a rebound case of the illness it’s supposed to be protecting you from.

Sounds exactly like the type of product that Fauci, Walensky, and the CDC would praise, doesn’t it?

Paxlovid is the entire Covid-pharmaceutical complex summarized perfectly. Created to solve a problem that was supposed to be fixed by another product…understudied, overhyped by the “experts,” and prematurely authorized by a desperate FDA…and ultimately shown to be mostly ineffective.

Ed Morrissey

Again, I can understand why the pharma industry rushed these products to market and why government incentivized them to do so ... in 2020-21. It's now four years later, and it's time to account for real data. Yet so far, only independent media outlets are even bothering to ask for it, and the pharmas and FDA, NIH, and NIAID are entirely silent about it. That has to change. 

Join the conversation as a VIP Member

Trending on HotAir Videos

Advertisement
Advertisement
Advertisement